Voyager Therapeutics struck a deal with Illinois-based AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein.
For Cambridge, Mass.-based Voyager, the strategic collaboration, could be worth more than $1 billion through Phase I development. Under terms of the deal, AbbVie will pay Voyager $65 million in upfront money. Voyager can earn an additional $245 million in preclinical and Phase I option payments. Voyager can also earn an additional $728 million in potential development, regulatory, and commercial milestone payments and royalties. Additionally, Voyager will be eligible to earn up to a total of $500 million in commercial milestones.
Per the details of the deal, Voyager will be responsible for the research and Phase I clinical activities and costs. Following completion of Phase I clinical development, AbbVie has an option to license the vectorized alpha-synuclein antibody program for further clinical development and global commercialization for indications including Parkinson’s disease and other synucleinopathies, the companies said.